Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention.
Extracellular cyclophilins have been well described as chemotactic factors for various leukocyte subsets. This chemotactic capacity is dependent upon interaction of cyclophilins with the cell surface signaling receptor CD147. Elevated levels of extracellular cyclophilins have been documented in several inflammatory diseases. We propose that extracellular cyclophilins, via interaction with CD147, may contribute to the recruitment of leukocytes from the periphery into tissues during inflammatory responses. In this study, we examined whether extracellular cyclophilin-CD147 interactions might influence leukocyte recruitment in the inflammatory disease allergic asthma. Using a mouse model of asthmatic inflammation, we show that 1) extracellular cyclophilins are elevated in the airways of asthmatic mice; 2) mouse eosinophils and CD4+ T cells express CD147, which is up-regulated on CD4+ T cells upon activation; 3) cyclophilins induce CD147-dependent chemotaxis of activated CD4+ T cells in vitro; 4) in vivo treatment with anti-CD147 mAb significantly reduces (by up to 50%) the accumulation of eosinophils and effector/memory CD4+ T lymphocytes, as well as Ag-specific Th2 cytokine secretion, in lung tissues; and 5) anti-CD147 treatment significantly reduces airway epithelial mucin production and bronchial hyperreactivity to methacholine challenge. These findings provide a novel mechanism whereby asthmatic lung inflammation may be reduced by targeting cyclophilin-CD147 interactions.
Gwinn
William M
WM
Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Medical Center, 2300 Eye Street NW, Washington, DC 20037, USA.
Damsker
Jesse M
JM
Falahati
Rustom
R
Okwumabua
Ifeanyi
I
Kelly-Welch
Ann
A
Keegan
Achsah D
AD
Vanpouille
Christophe
C
Lee
James J
JJ
Dent
Lindsay A
LA
Leitenberg
David
D
Bukrinsky
Michael I
MI
Constant
Stephanie L
SL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications* / Q000188:drug therapy*; D051926:Basigin / Q000187:drug effects / Q000276:immunology*; D015153:Blotting, Western; D016535:Bronchial Hyperreactivity / Q000276:immunology; D001985:Bronchial Provocation Tests; D018893:Bronchoalveolar Lavage; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D021983:Cyclophilins / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D045604:Extracellular Fluid / Q000737:chemistry / Q000276:immunology; D005260:Female; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009077:Mucins / Q000187:drug effects; D020556:Neutrophil Infiltration / Q000276:immunology; D010047:Ovalbumin / Q000276:immunology; D011014:Pneumonia / Q000209:etiology* / Q000517:prevention & control*; D011657:Pulmonary Eosinophilia / Q000188:drug therapy / Q000209:etiology
D000911:Antibodies, Monoclonal; C497887:Bsg protein, mouse; D009077:Mucins; D051926:Basigin; D010047:Ovalbumin; D021983:Cyclophilins